| Literature DB >> 35131445 |
Jacob H L Thomas1, Liang Lui2, Andrew Abell3, William Tieu4, Andrew A Somogyi2, Juliana E Bajic3, Mark R Hutchinson5.
Abstract
Toll-like receptors (TLR) have been proposed as a site of action that alters opioid pharmacodynamics. However, a comprehensive assessment of acute opioid antinociception, tolerance and withdrawal behaviours in genetic null mutant strains with altered innate immune signalling has not been performed. Nor has the impact of genetic deletion of TLR2/4 on high-affinity opioid receptor binding. Here we show that diminished TLR signalling potentiates acute morphine antinociception equally in male and female mice. However, only male TIR8 null mutant mice showed reduced morphine analgesia. Analgesic tolerance was prevented in TLR2 and TLR4 null mutants, but not MyD88 animals. Withdrawal behaviours were only protected in TLR2-/- mice. In silico docking simulations revealed opioid ligands bound preferentially to the LPS binding pocket of MD-2 rather than TLR4. There was no binding of [3H](-)-naloxone or [3H]diprenorphine to TLR4 in the concentrations explored. These data confirm that opioids have high efficacy activity at innate immune pattern recognition binding sites but do not bind to TLR4 and identify critical pathway and sex-specific effects of the complex innate immune signalling contributions to opioid pharmacodynamics. These data further support the behavioural importance of the TLR-opioid interaction but fail to demonstrate direct evidence for high-affinity binding of the TLR4 signalling complex to ligands.Entities:
Keywords: Analgesia; Binding kinetics; Morphine; Opioid receptor; Tolerance; Toll-like receptors; Withdrawal
Mesh:
Substances:
Year: 2022 PMID: 35131445 DOI: 10.1016/j.bbi.2022.02.001
Source DB: PubMed Journal: Brain Behav Immun ISSN: 0889-1591 Impact factor: 7.217